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Three new anionic dioxidovanadium(V) complexes (HNEt3)[VO2(L)
1–3] (1–3) of tridentate binegative aroyl-
hydrazone ligands containing the azobenzene moiety were synthesized and structurally characterized.
The aroylhydrazone ligands (H2L
1–3) were derived from the condensation of 5-(arylazo) salicylaldehyde
derivatives with the corresponding aroyl hydrazides. All the synthesized ligands and metal complexes
were successfully characterized by several physicochemical techniques, namely, elemental analysis,
electrospray ionization mass spectrometry, spectroscopic methods (IR, UV-vis and NMR), and cyclic
voltammetry. Single-crystal X-ray diffraction crystallography of 1–3 revealed five-coordinate geometry,
where the ligand coordinates to the metal centre in a binegative tridentate O, N, O coordinating anion
and two oxido-O atoms, resulting in distortion towards the square pyramidal structure. The complexes
were further evaluated for their in vitro cytotoxicity against HeLa and HT-29 cancer cell lines. All the
complexes manifested a cytotoxic potential that was found to be comparable with that of clinically
referred drugs, while complex 3 proved to be the most cytotoxic among the three complexes for both
cell lines, which may be due to the synergistic effect of the naphthyl substituent in the azohydrazone
ligand environment coordinated to the vanadium metal. The synthesized complexes 1–3 were probed
as catalysts for the oxidative bromination of thymol and styrene as a functional mimic of vanadium halo-
peroxidases (VHPOs). All the reactions provided high percentages of conversion (490%) with a high
turnover frequency (TOF) in the presence of the catalysts 1–3. In particular, for the oxidative bromination
of thymol, the percentage of conversion and TOF were in the ranges of 98–99% and 5380–7173 (h1),
respectively. Besides, 3 bearing the naphthyl substituent showed the highest TOF among all the com-
plexes for the oxidative bromination of both thymol and styrene.
Paramount interest has been given to the coordination chemistry
of vanadium complexes due to their significance in various bio-
chemical, pharmacological, and catalytic activities.1 As vanadium
metal possesses the ability to assume various oxidation states of 3+,
4+ and 5+, it shows diverse biological roles and interacts with
diﬀerent biomolecules.2 For instance, various marine as well as
terrestrial organisms utilize vanadium for their life processes;3
vanadium haloperoxidase (V-HPOs) found in marine algae can
facilitate the oxidative halogenation of aromatic organic complexes
in the presence of organic hydroperoxides, hydrogen peroxide or
molecular oxygen.4 It also plays a vital role in enzymes, such
as vanadium-dependent nitrogenases, nitrate reductases and
amavadin.5,6 Furthermore, the pharmacological potential of
vanadium complexes has been successfully shown in the treat-
ment of type I and type II diabetes, while in the past decade,
they have also been studied as anti-tumor agents.7
In this context, vanadium complexes have exhibited promis-
ing cytotoxicity against a wide spectrum of human cancer cell
lines.7 These metal complexes have shown reduced side eﬀects,
more potent action, better selectivity and higher cytotoxicity in
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both in vitro and in vivo models.1b,8 Besides, a vanadium complex,
i.e., Metvan can induce apoptosis in testicular and ovarian tumors.9
Vanadium complexes demonstrate apoptosis-inducing ability along
with higher cytotoxicity in comparison to free ligands.10 As the
pharmacological properties of metal complexes are a result of both
the metal centre and the ligand backbone, it is highly beneficial to
employ bioactive ligands in the design of metal-based drugs. Such
ligands include aroylhydrazones –NH–N = CRR0 (R and R0 = H,
alkyl, aryl); they are known to manifest a wide variety of properties
such as antimicrobial and antitumor activities and therefore
represent an important class of compounds with profound applica-
tions in chemistry and medicine.11 In addition, the use of the
azobenzene moiety in the ligand backbone is of considerable
interest because it exhibits interesting biological properties. As
DNA is the primary intracellular target of any anti-cancer drug,
these azobenzene derivatives, which usually exist in their stable
trans-isomer form, are known to interact with DNA through the
base-stacking method.12 Furthermore, the higher substitution
and planarity of ligands such as benzyl and naphthyl groups
can also lead to an enhanced DNA interaction.13
The capability of vanadium to easily interconvert between
various oxidation states, its high aﬃnity for oxygen and also its
Lewis acidic nature make vanadium appropriate and relevant
for applications in redox and Lewis acid-catalyzed reactions.14
Consequently, vanadium has been widely used in the catalytic
oxidation reactions of various organic substrates including
sulphoxidation,15 bromination,16 oxidation of alcohols,17 epox-
idation of olefins,18 and hydroxylation of aromatic hydrocarbons.19
Moreover, the combination of vanadium metal with aroylhydra-
zone ligands is a good choice for catalytic oxidation because of the
latter’s ability to resist oxidation.20 Therefore, the use of low-cost,
environmental friendly vanadium aroylhydrazone complexes,
which can also alleviate the oxidizing nature of the oxidants,21
aﬀording new-generation catalysts with a high turnover number
(TON), selectivity and sustainability, is the need of the hour.
As a part of our ongoing research on the oxidovanadium(V)
metal complexes of aroylazines in relation to their biological10a–c
and catalytic applications22a and some non-oxido vanadium(IV)
complexes, which are very stable in solid as well as in the solution
state,22b in the present work, we reported the synthesis of three new
dioxidovanadium(V) complexes (HNEt3)[VO2(L)
1–3] (1–3) of triden-
tate binegative aroylhydrazone ligands containing the azobenzene
moiety H2L
1–3. Also, it would be relevant to mention here that
hydrogen bonding interactions for the design and synthesis of
extended frameworks via supramolecular interactions have been on
the forefront of research, especially in the fields of molecular
recognition and engineering of molecular solids.23 In this study,
we used triethylamine as a source of counterions for the formation
of polymeric aggregates. These counterions play a pivotal role,
increasing the stability of the components of the supramolecular
interactions through hydrogen bonding networks by charge neu-
tralization. Furthermore, these complexes also exhibited enhanced
water solubility, making them important subjects for biological and
catalytic studies. All the synthesized ligands and metal complexes
were successfully characterized by elemental analysis as well as
through various spectroscopic techniques (IR, UV-vis and NMR).
Considering the above-discussed biological and catalytic relevance
of vanadium complexes containing O, N donor ligands, we studied
the complexes for their antiproliferative efficacy against human
cervical cancer (HeLa) and human colorectal adenocarcinoma
(HT-29) cell lines and also for their catalytic potential in the
oxidative bromination of thymol and styrene as a functional mimic
of vanadium haloperoxidases (VHPOs).
Experimental section
General materials and methods
All the chemicals were procured commercially and were used in
their original form. VO(acac)2 was prepared as described in the
literature.24 Reagent-grade solvents were dried and distilled prior to
use. HeLa and HT-29 cell lines were obtained from the National
Centre of Cell Science (NCCS), Pune, India. Dulbecco’s modified
Eagle medium (DMEM), Dulbecco’s phosphate buﬀered saline
(DPBS), trypsin EDTA solution, fetal bovine serum (FBS), and anti-
biotic–antimitotic solution were procured from Himedia, Mumbai,
India. MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium)
and DAPI (40,6-diamidino-2-phenylindole dihydrochloride) were
purchased from Sigma-Aldrich, India. Elemental analyses were
performed on a Vario ELcube CHNS Elemental Analyzer. IR spectra
were recorded on a PerkinElmer SpectrumRXI spectrometer. 1H and
13C NMR spectra were studied with a Bruker Ultrashield 400 MHz
spectrometer using SiMe4 as an internal standard, and
51V was
studied using VOCl3 as an internal standard. Electronic spectra were
examined on a Lamda25, PerkinElmer spectrophotometer. Electro-
chemical data were collected using a PAR electrochemical analyser
and a PC-controlled potentiostat/galvanostat (PAR 273A) at 298 K in a
dry nitrogen atmosphere. Cyclic voltammetry experiments were
carried out with a platinum working electrode, a platinum auxiliary
electrode and an SCE reference electrode. Commercially available
TBAP (tetrabutyl ammonium perchlorate) was dried and used as a
supporting electrolyte for recording the cyclic voltammograms of the
complexes. ESI-MS of the complexes was conducted on a Bruker
MAT SSQ 710 spectrometer, employing a complex concentration of
100 pmol mL1. A Shimadzu 2010 plus gas-chromatograph fitted
with an Rtx-1 capillary column (30 m  0.25 mm  0.25 mm) and a
flame ionization detector (FID) were utilized to analyse the reaction
products. The quantification of the products was made on the basis
of the relative peak area of the respective product. The identification
of these products was performed using a GC-MSmodel PerkinElmer,
Clarus 500 and the fragments of each product were compared with
the available library. The percent conversion of the substrate and the
selectivity of the products were calculated from the GC data using
the following formulae:
%Conversion of substrate
¼ 100 Peak area of a substrate
Total area of a substrateþ products 100
%Selectivity of a product ¼ Peak area of a product
Total area of products
 100
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Caution: Although no problems were encountered during
the course of this work, attention must be drawn to the
potentially explosive nature of perchlorates.
Synthesis of ligands [H2L
1–3]
First, 5-(arylazo) salicylaldehyde containing the azobenzene
moiety was prepared, as reported in the literature.25 The ligands
[H2L
1–3] were then synthesized by condensing 5-(arylazo) salicyl-
aldehyde with their corresponding aroyl hydrazides (benzoic
hydrazide) (H2L
1), salicyclic hydrazide (H2L
1) and 3-hydroxy-2-
naphthoic hydrazide (H2L
1) at a 1 : 1 molar ratio in an ethanolic
medium. The resulting light orange product was filtered, washed
and dried over fused CaCl2.
H2L
1: Yield: 0.24 g (72%). Anal. calcd for C20H16N4O2: C,
69.76; H, 4.68; N, 16.27. Found: C, 69.54; H, 4.59; N, 16.10%.
FTIR (KBr, nmax/cm1): n(O–H) 3412, n(N–H) 3056, n(CQO)
1675, n(CQN) 1612, n(NQN) 1494. 1H NMR (400 MHz,
DMSO-d6): d (ppm) = 12.23 (s, 1H, –OH), 11.83 (s, 1H, –NH),
8.78 (s, 1H, –CH), 8.25–7.13 (m, 13H, aromatic). 13C NMR (100
MHz, DMSO-d6): d (ppm) = 168.49, 164.67, 152.48, 146.82
145.60, 133.26, 132.50, 131.35, 129.87, 129.03, 128.16, 126.30,
123.84, 122.75, 120.26, 117.78.
H2L
2: Yield: 0.28 g (71%). Anal. calcd for C20H16N4O3: C,
66.66; H, 4.48; N, 15.55. Found: C, 66.88; H, 4.89; N, 15.05%.
FTIR (KBr, nmax/cm
1): n(O–H) 3202, n(N–H) 3059, n(CQO)
1644, n(CQN) 1607, n(NQN) 1493. 1H NMR (400 MHz,
DMSO-d6): d (ppm) = 12.10 (s, 1H, –OH), 11.88(s, 1H, phenolic
OH) 11.82 (s, 1H, –NH), 8.8 (s, 1H, –CH), 8.2–6.9 (m, 12H,
aromatic). 13C NMR (100 MHz, DMSO-d6): d (ppm) = 163.55,
160.58, 153.64, 150.89, 148.71, 146.99, 146.49, 145.36, 141.78,
130.37, 128.78, 126.45, 123.91, 122.57, 121.33, 118.72, 114.81,
112.87.
H2L
3: Yield: 0.26 g (69%). Anal. calcd for C24H18N4O3: C,
70.23; H, 4.42; N, 13.65. Found: C, 70.68; H, 4.47; N, 13.75%.
FTIR (KBr, nmax/cm
1): n(O–H) 3161, n(N–H) 3056, n(CQO)
1633, n(CQN) 1625, n(NQN) 1522. 1H NMR (400 MHz,
DMSO-d6): d (ppm) = 12.13 (s, 1H, –OH), 12.01 (s, 1H, naphthoic
OH), 11.82 (s, 1H, –NH), 8.81 (s, 1H, –CH), 8.48–7.15 (m, 14H,
aromatic). 13C NMR (100 MHz, DMSO-d6): d (ppm) = 164.23,
160.71, 154.47, 152.47, 147.27, 145.59, 136.37, 131.40, 130.79,
129.90, 129.15, 128.78, 127.24, 126.34, 124.31, 123.53, 122.76,
122.64, 120.65, 120.23, 117.80, 111.03.
Synthesis of dioxidovanadium(V) complexes (HNEt3)[VO2(L)
1–3]
(1–3)
The (HNEt3)[VO2(L)
1–3] (1–3) complexes were synthesized by
refluxing the azohydrazone ligands [H2L
1–3] and [VO(acac)2] in
an alcohol medium using triethylamine as a base for 3 h. Dark
brown crystals, suitable for X-ray analysis, were obtained from
the filtrate after 2–4 days.
(HNEt3)[VO2(L)
1] (1). Yield: 0.28 g (52%). Anal. calcd for
C31H44N5O4V: C, 61.88; H, 7.37; N, 11.64. Found: C: 61.72; H:
7.90; N: 11.47%. FTIR (KBr, nmax/cm
1): n(CQN) 1614, n(NQN)
1463, n(VQO) 942, 954. UV-vis (DMSO): lmax, nm (e, mol1 cm1):
396(8933), 344(10600), 261(6133).1H NMR (400 MHz, DMSO-d6):
d (ppm) = 9.20 (s, 1H, –CH), 8.91–6.94 (m, 13H, aromatic),
3.08 (m, 6H, –CH2), 1.16 (t, 9H, –CH3).
13C NMR (100 MHz,
DMSO-d6): d (ppm) = 170.55, 168.58, 152.46, 146.71, 146.62,
146.49, 145.56, 131.37, 129.88, 126.54, 123.29, 122.75, 120.41,
117.72, 115.81, 112.67, 46.27, 9.22. 51V NMR (105 MHz, DMSO-
d6, ppm): d = 529. ESI-MS: (CH3OH; negative ion mode): m/z
425.1 [M  (Et3NH)+]+.
(HNEt3)[VO2(L)
2] (2). Yield: 0.34 g (55%). Anal. calcd for
C31H44N5O4V: C, 61.88; H, 7.37; N, 11.64. Found: C: 61.01; H:
7.70; N: 11.10%. FTIR (KBr, nmax/cm
1): n(O–H) 3550, n(CQN)
1607, n(NQN) 1479, n(VQO) 947, 960. UV-Vis (DMSO): lmax, nm
(e, mol1 cm1): 395(8405), 346(10 328), 265(6620). 1H NMR
(400 MHz, DMSO-d6): d (ppm) = 12.15 (s, 1H, phenolic OH), 9.31
(s, 1H, –CH), 9.05–6.98 (m, 12H, aromatic), 3.08 (m, 6H, –CH2),
1.16 (t, 9H, –CH3).
13C NMR (100 MHz, DMSO-d6): d (ppm) =
170.99, 168.28, 159.09, 157.00, 152.58, 143.76, 133.40, 131.52,
130.94, 129.86, 129.57, 126.14, 122.59, 121.57, 119.89, 119.28,
117.06, 115.72, 46.22, 9.12. 51V NMR (105 MHz, DMSO-d6, ppm):
d = 537. ESI-MS: (CH3OH; negative ion mode): m/z 441.2
[M  (Et3NH)+]+ (2).
(HNEt3)[VO2(L)
3] (3). Yield: 0.31 g (57%). Anal. calcd for
C35H46N5O5V: C, 58.49; H, 6.45; N, 9.75. Found: C: 58.07; H:
6.69; N: 9.86%. FTIR (KBr, nmax/cm1): n(O–H) 3442, n(CQN)
1609, n(NQN) 1469, n(VQO) 947, 959. UV-Vis (DMSO): lmax, nm
(e, mol1 cm1): 390(9027), 342(10 756), 263(6135). 1H NMR
(400 MHz, DMSO-d6): d (ppm) = 12.04 (s, 1H, naphthoic OH),
9.37 (s, 1H, –CH), 8.52–6.98 (m, 14H, aromatic), 3.08 (m, 6H,
–CH2), 1.15 (t, 9H, –CH3).
13C NMR (100 MHz, DMSO-d6): d
(ppm) = 170.45, 168.39, 157.72, 155.22, 152.57, 143.81, 136.53,
131.63, 130.97, 129.86, 129.26, 128.48, 127.36, 126.33, 126.28,
123.86, 122.59, 121.64, 119.97, 119.58, 118.18, 110.75, 46.26,
9.15. 51V NMR (105 MHz, DMSO-d6, ppm): d = 537. ESI-MS:
(CH3OH; negative ion mode): m/z 491.1 [M  (Et3NH)+]+.
Crystallography
Single crystals of the complexes (1–3) suitable for X-ray diffraction
study were obtained at room temperature via slow evaporation
from their ethanol/methanol solutions. Crystals of complex 1–2
were mounted on a loop in oil on a Stoe IPDS2 diffractometer
equipped with an Oxford Cryosystem open flow cryostat and an
Mo Ka radiator (l) 0.71073 Å. The crystals were kept at 298(2) K (1)
and at (2) during data collection, while the X-ray diffraction data
of complex (3) were collected at 100(2) K on a SuperNova
diffractometer (Rigaku) with a CCD detector and Cu Ka radiation.
Crystallographic data and details of refinement of all the com-
plexes are summarized in Table 1. The structures were solved
through Olex226 with the help of the ShelXT27 structure solution
program using intrinsic phasing and refined with the ShelXL28
refinement package using least squares minimisation. All hydro-
gen atoms were initially located in electron-density difference
maps. C–H hydrogen atoms were constrained to idealized posi-
tions, with C–H = 0.95–1.00 Å and with Uiso(H) = 1.5Ueq(C) for
methyl hydrogen atoms and Uiso(H) = 1.2Ueq(C) for others. The
ammonium and hydroxyl hydrogen atoms were freely refined
without any constraints or restraints, while the non-hydrogen
atoms were refined anisotropically. PLATON software29 was used
to validate the crystallographic data.
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Cytotoxic study
MTT assay. The in vitro cytotoxicity of 1–3 was studied
against human cervical cancer (HeLa), colon cancer (HT-29)
and non-cancerous human epidermal keratinocyte cells (HaCaT)
through an MTT dye reduction assay. Prior to the experiment,
the cells were maintained in DMEM media supplemented with
10% FBS and penicillin–streptomycin solution in a humidified
(95% humidity) CO2 incubator (5% CO2) at 37 1C with uniform
passages at 70–80% confluence. For the present study, the cells
were harvested by trypsinization and seeded at a concentration
of 1  104 cells per well into a 96-well plate. After 12 h of initial
seeding, the HeLa and HT-29 cells were subjected to treatment
with six different concentrations (100, 50, 10, 7, 5, 3 mg mL1) of
each complex, while the HaCaT cells were subjected to treatment
with four different concentrations (100, 50, 10, 5 mg mL1) of
each complex. The final working concentration of the complexes
was prepared in complete DMEM media. Untreated cells
cultured in media alone were taken as the control. Subsequently,
after 12, 24 and 48 h, the viability of the cells was tested by MTT
assay, and the optical density of these cells was measured at
595 nm using a microplate reader spectrophotometer.10a The
cytotoxicity of the compounds was checked by measuring the
percentage cell viability of the cells with respect to the control.30
The experiments were performed four times (n = 4), and the data
were expressed as mean  SD. Single variance ANOVA under
95% confidence interval was used to evaluate the statistical
significance of the data.
Nuclear staining assay. The nuclear morphological change
during the cell death of the cells in response to treatment with
the complexes (1–3) was studied through the DAPI staining
method.31 HeLa and HT-29 cells were treated with test
compounds at a concentration of 10 mg mL1 for 24 h. After
treatment, the cells were fixed with 4% formaldehyde for
15 min, followed by permeabilization with 0.1% Triton X-100.
They were subsequently stained with DAPI for 5 min at 37 1C
and were washed with PBS. Untreated cells were used as the
control. The cells were then examined by confocal microscopy
(Leica, SP8).
Catalytic reactions of (HNEt3)[VO2(L)
1–3] (1–3)
Oxidative bromination of thymol. The oxidative bromination
of thymol was carried out using complexes 1–3 as the catalyst
precursors. As a representative, thymol (1.5 g, 10 mmol) was
added to an aqueous solution (20 mL) of KBr (1.19 g, 10 mmol)
and 30% aqueous H2O2 (1.13 g, 10 mmol) in a 50 mL reaction
flask. The catalyst (0.0005 g) and 70% HClO4 (1.43 g, 10 mmol)
were added, and the reaction mixture was stirred at room
temperature. In all batches, the experimental conditions (e.g.,
stirring speed, the size of the magnetic bar and reaction flask)
were similarly maintained. After 1 h, the products were
extracted in the hexane layer and injected into the GC. The
identities of all the products were confirmed by GC-MS.
Oxidative bromination of styrene. Styrene (1.04 g, 10 mmol)
was added to an aqueous solution (20 mL) of KBr (1.19 g,
10 mmol) and 30% aqueous H2O2 (1.13 g, 10 mmol) in a 50 mL
Table 1 Crystal data and structure refinement details for 1–3
Complex 1 2 3
Empirical formula C26H30N5O4V C26H30N5O5V C30H32N5O5V
Formula weight 527.49 543.49 593.55
Temperature 298(2) K 200(2) K 100 K
Wavelength [Å] 0.71073 0.71073 1.54184
Crystal system Monoclinic Monoclinic triclinic
Space group P21 P21 P%1
Unit cell dimensions
a [Å] 6.9776(6) 6.8790(3) 9.1706(2)
b [Å] 8.6271(7) 8.5804(3) 11.5525(2)
c [Å] 22.0397(18) 22.3944(11) 15.4622(3)
a [1] 90 90 109.451(2)
b [1] 94.002(7) 91.071(4) 93.169(2)
g [1] 90 90 112.197(2)
Volume [Å3] 1323.48(19) 1321.59(10) 1399.04(5)
Z 2 2 2
Density calculated 1.324 mg m3 1.366 mg m3 1.409 g cm3
Absorption coeﬃcient [mm1] 0.415 0.420 3.37
F(000) 552 568 620
Crystal size [mm3] 0.13  0.1  0.05 0.26  0.13  0.07 0.24  0.18  0.07
Theta range for data collection [1] 5.072 to 50.428 3.638 to 50.362 4.4 to 76.4
Reflections collected 17 318 16 895 59 124
Independent reflections, R(int) 4686, 0.1554 4671, 0.0744 5860
Data completeness [%] 98.8% 98.9% 99.8
Data/restraints/parameters 4684/66/294 4671/3/340 5860/0/436
Goodness-of-fit on F2 0.873 1.002 1.09
Final R indices [I 4 2sigma(I)] R1 = 0.0499, wR2 = 0.0919 R1 = 0.0643, wR2 = 0.1478 R1 = 0.039, wR2 = 0.113
R indices (all data) R1 = 0.1219, wR2 = 0.1165 R1 = 0.0880, wR2 = 0.1608 R1 = 0.0394, wR = 0.1129
Absolute structure parameter 0.01(5) 0.019(17) —
Extinction coeﬃcient n/a n/a n/a
Largest diﬀ. peak and hole e Å3 0.217 and 0.37 1.06 and 0.32 0.71 and 0.58
CCDC number 1903090 1903091 1902693
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reaction flask. The catalyst (0.0005 g) and 70% HClO4 (1.43 g,
10 mmol) were added, and the reaction mixture was stirred at
room temperature. In all batches, the experimental conditions
(e.g., stirring speed, the size of the magnetic bar and reaction
flask) were similarly maintained. The eﬀects of various para-
meters such as the amount of catalyst, oxidant, NaHCO3, and
solvent were checked to optimize the conditions for the best
performance of the catalyst. After 1 h, the products were
extracted in the hexane layer and injected into the GC. The
identities of all the products were confirmed by GC-MS.
Results and discussion
Synthesis
In the present study, three dioxidovanadium(V) complexes
(HNEt3)[VO2(L)
1–3] (1–3) were synthesized from azohydrazone
ligands [H2L
1–3]. The synthesis of the complexes is summarized
in Scheme 1. The reaction of azohydrazone with VO(acac)2
proceeded smoothly at a molar ratio of 1 : 1 in an alcohol
medium in the presence of triethylamine as a base. Single
crystals of complexes 1–3 were obtained directly from the slow
evaporation of the filtrate of the reaction mixture. Furthermore,
the purity of these complexes was confirmed by elemental
analyses. NMR spectra and ESI-MS results were consistent with
the X-ray structures. The complexes were soluble in CH3CN,
ethanol, methanol, DMF, and DMSO and partially soluble in
water. Magnetic susceptibility and molar conductivity data
revealed that all the complexes (1–3) were diamagnetic and
electrically non-conducting in solution. The detailed characteriza-
tion of all the complexes has been discussed in the corresponding
sections (IR, UV-Vis, NMR, ESI-MS and X-ray crystallography).
Spectral characteristics
The spectral characteristics of all the ligands (H2L
1–3) and com-
plexes (1–3) are provided in the Experimental section. The FTIR
spectra of the ligands show a broad band in the range of 3202–
3412 cm1 due to the stretching vibration of the –OH group. Due
to the presence of the –NH group in the ligand, a broad band was
observed at 3056–3059 cm1, while the band for –CQO stretching
frequency was obtained in the range of 1644–1675 cm1.
The bands for the stretching frequencies of –CQN and
–NQN were obtained in the ranges of 1612–1625 cm1 and
1494–1522 cm1, respectively. The disappearance of the –NH,
–CQO, and –OH stretching bands in the IR spectra of the
complexes (1–3) indicated the formation of metal complexes.
However, there was a peak for the pending phenolic OH (2) and
naphthoic OH (3) groups present in the ligand backbone in the
range of 3442–3550 cm1. The sharp peak at 1609–1614 cm1
was probably due to the –CQN– moiety in the formed
complex.32 The presence of two strong peaks in the range of
942–960 cm1 was due to VQO stretching, which indicated the
presence of the dioxido group in the complexes.10a,c,33
The electronic spectra of all the complexes were recorded in
DMSO and showed a similar pattern. They exhibited medium
intensity bands in the range of 396–390 nm, which could be
assigned to ligand-to-metal charge transfer (LMCT); they also
displayed strong intensity bands within the 261–342 nm range
due to ligand-centered transitions.32a,b A representative absor-
bance spectrum of 1 is given in Fig. 1.
The 1H and 13C NMR spectra of all ligands and their
corresponding compounds were recorded in DMSO-d6; the data
are given in the experimental section. The 1H NMR spectrum of
the free ligands exhibits singlet resonance in the range of
d = 12.23–11.88 ppm due to the –OH group. However, the
ligands H2L
2 and H2L
3 exhibit one extra singlet peak in the
d = 12.01–11.88 ppm region for phenolic OH (H2L
2) and
Scheme 1 Schematic representation for the synthesis of (HNEt3)[VO2(L)
1–3] (1–3).
Fig. 1 UV-vis spectra of 1 (1.5  104 M) in DMSO.
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naphthoic OH (H2L
3). The singlets in the d = 11.83–11.82 ppm and
d = 8.80–8.78 ppm ranges are due to the –NH group and the
azomethine –CH proton, respectively. The aromatic protons of the
ligands were clearly observed in the expected d = 8.48–6.9 ppm
region as multiplets.32a,b In the NMR spectra of complexes 1–3,
the peak for the aromatic –OH and –NH protons disappeared due
to deprotonation at the time of complexation, while the peak in
the d = 12.15–12.04 ppm region was retained for that of the
pending phenolic OH (2) and naphthoic OH (3) groups present in
the ligand backbone. The signal for the azomethine –CH proton
in the complexes appeared in the range of d = 9.37–9.20.
The aromatic signals for the complexes appeared in the range
of d = 9.0–6.9 ppm as a multiplet. There were two additional
peaks observed at the aliphatic region, i.e., at d = 3.08 and at
d = 1.15 ppm, which could be attributed to the presence of a
triethylamine moiety. In the 13C NMR spectra of the ligands
H2L
1–3, spectral signals for aromatic carbons were found in the
downfield region in the range of d = 168.49–111.03 ppm. In
contrast, in the 13C NMR spectra of complexes 1–3, signals for
aromatic carbons were found in the downfield region in the range
of d = 170.99–110.75 ppm. Also, two additional peaks were found
in the upfield region (d = 46.27–9.12) due to the presence of two
aliphatic carbon atoms (–CH2CH3) of the triethylamine group.
The 51V NMR spectra of 1–3 showed a singlet from d 537 to
529 ppm. The chemical shifts obtained in this range were
typical for the dioxidovanadium(V) species.10a,c
The mass spectra of all the complexes were recorded in
methanol in the ESI mode by applying a complex concentration
of 100 pmol mL1. The characteristic ion peaks for 1–3 appear at
m/z 425.1 [M  (Et3NH)+]+, 441.2 [M  (Et3NH)+]+ and 491.1
[M  (Et3NH)+]+, respectively, in the negative ion mode. Fig. S1
(ESI†) depicts the representative ESI-MS spectrum of 1.
Electrochemical properties
The redox properties of the complexes 1–3 were studied in
DMSO solutions in the presence of 0.1 M TBAP as the electro-
lyte using SCE as the reference electrode, Pt as the working
electrode, and a Pt wire as the auxiliary electrode at variable
scan rates of 50, 100 and 150 mV s1. The voltammograms of all
the complexes show a similar pattern, and the redox potential
data of all the complexes are summarized in Table 2. As a
representative, the voltammogram of 1 has been discussed
herein and depicted in Fig. 2; the voltammograms for 2 and 3
are given in Fig. S2 and S3 (ESI†). There were irreversible single-
electron cathodic responses of 1 at 0.33, 0.66 and 1.25 V
and an anodic response at 0.71 V, which may be assigned to
ligand-centred reduction and oxidation, respectively. Conversely,
the complex displayed a quasi-reversible single-electron trans-
fer redox process at the E1/2 value of 1.61 V, which was
ascribed to the V(V)/V(IV) reduction couple of 1 containing the
reduced ligand.34
As a representative, the voltammogram of the ligand H2L
1 is
shown in Fig. S4 (ESI†). The voltammograms at diﬀerent scan
rates were compared to confirm the quasi-reversible nature of
the redox processes. Also, identical experimental conditions
were maintained to verify the single-electron processes, and
its current height was compared with that of the standard
ferrocene–ferrocenium couple.
X-ray structure description
Even though the preliminary characterization data (elemental
analysis, 1H and 13C NMR and IR) suggested the presence of a
ligand, two oxido groups and a counter ion in complexes 1–3,
they could neither manifest any definite stereochemistry for the
complexes nor predict the coordination mode of H2L
1–3.
In order to validate the coordination mode of the ligands
and the supramolecular geometries possible in these complexes,
the structures of 1–3 were determined via X-ray crystallography.
The X-ray structures of the complexes revealed that all the
evidence provided by the 1H NMR spectra was correct. The
relevant bond parameters are mentioned in Table 3, while
the molecular structure along with the atom numbering scheme
for 1–3 is depicted in Fig. 3. The structure revealed that the
vanadium atom, which is present in a penta-coordinated fash-
ion, was bound by a tridentate binegative anion coordinating
via phenolate oxygen – O(2), imine nitrogen – N(2) and enolic
oxygen – O(1) and two oxido – O(3), O(4) atoms; the charge of
this moiety was balanced by a triethylamine cation. The result-
ing O4N donor set in complexes 1–3 was distorted toward
square pyramidal geometry based on a t value in the range of
0.08–0.24,29 which is evident from the ideal values of 0.0 and
1.0 for square pyramidal and trigonal bipyramidal geometries,
respectively.35
The azohydrazone ligands form six-membered and five-
membered chelate rings at the V(V) metal center with O(2)–
V(1)–N(2) and O(1)–V(1)–N(2) bite angles of 82.1(2)1–81.79(6)1
and 73.9(2)1–73.2(2)1, respectively. One of the two oxido groups,
Table 2 Cyclic voltammetric resultsa of 1–3 at 298 K in DMSO
Complex Ec1/2 (V) DE
c
P (mV)
1 1.61 249
2 1.58 248
3 1.55 240
a In DMSO at variable scan rates of 50, 100 and 150mV s1. Ec1/2 = (E
a
P + E
c
P)/2,
where EaP and E
c
P are the anodic and cathodic peak potentials vs. SCE,
respectively. DEcP = E
a
P  EcP.
Fig. 2 Cyclic voltammogram of 1 (103 M) in DMSO.
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i.e., O(4) is located terminally at the apical position of the
square pyramid and trans to the imine nitrogen N(2), while the
other oxido group O(3) is located in the axial plane. The V–O(4)
bond distances are slightly longer than those of V–O(3) due to
the trans effect; however, such bond lengths are longer than
those of the monoalkoxido vanadium(V) complexes containing
only one terminal oxygen atom.32b The angle between the two
oxido atoms O(3) and O(4), i.e., O(3)–V(1)–O(4) is in the range of
110.31(8)1–109.1(3)1. Both VQO bonds are shorter than their
corresponding V–O (phenolate) and V–O (enolate) bonds,
suggesting the stronger binding of the oxido group compared
to those of the phenolate and enolate oxygen atoms.36
The supramolecular architectures showed that the complexes
were bound to the triethylamine cationmoiety by VQO(4)  H–N(5)
hydrogen bonding (red dotted lines, Fig. 4), whereas there was
additional intramolecular hydrogen bonding O(5)–H  N(1)
present for complexes 2 and 3 (blue dotted lines, Fig. 4(b)
and (c)), involving the hydrogen of naphthoic OH and the
imine nitrogen N(1) atom. The detailed parameters of the
classical hydrogen bonding of the complexes (1–3) are listed
in Table 4.
Cytotoxic study
MTT assay. Following successful synthesis and characteriza-
tion, the in vitro cytotoxicity of the complexes 1–3 was evaluated
by determining the viability of cervical cancer (HeLa) and
human colon cancer (HT-29) cell lines through MTT assays.
These studies were performed in order to probe and observe the
influence of the vanadium metal centre in the aroylhydrazone
ligand environment appended with an azobenzene moiety on
the antiproliferative efficacy of the reported complexes. The
analysis revealed that all the complexes were quite effective in
killing the cancer cells and were highly cytotoxic even at a low
concentration of 3 mg mL1. It was also observed that upon
increasing the time of exposure of the complexes (3 mg mL1)
from 12 to 24 h, there was gradual decrease in HeLa and HT-29
cell viabilities (Fig. 5A and B). Following that, after 48 h of
exposure, there were almost 60 and 70% cell deaths with respect
to the control for HeLa and HT-29 cell lines, respectively, at the
highest concentration of the complexes (100 mg mL1) tested
Table 3 Selected geometric parameters for 1–3
1 2 3
Bond distances (Å)
V(1)–O(1) 1.956(5) 1.970(5) 1.982(1)
V(1)–O(2) 1.903(5) 1.910(5) 1.902(1)
V(1)–O(3) 1.610(5) 1.603(5) 1.611(1)
V(1)–O(4) 1.636(5) 1.639(5) 1.636(2)
V(1)–N(2) 2.146(6) 2.124(6) 2.150(1)
N(1)–N(2) 1.398(8) 1.416(8) 1.392(2)
N(3)-N(4) 1.226(8) 1.233(10) 1.258(2)
Bond angles (1)
O(1)–V(1)–N(2) 73.2(2) 73.9(2) 73.53(5)
O(2)–V(1)–N(2) 82.1(2) 81.2(2) 81.79(6)
O(2)–V(1)–O(1) 148.0(2) 149.1(2) 151.65(6)
O(3)–V(1)–N(2) 106.8(2) 109.0(3) 112.22(7)
O(3)–V(1)–O(1) 102.0(3) 101.4(3) 101.14(7)
O(3)–V(1)–O(2) 104.4(3) 103.8(3) 100.96(7)
O(3)–V(1)–O(4) 109.7(3) 109.1(3) 110.31(8)
O(4)–V(1)–N(2) 143.1(3) 141.5(3) 136.99(7)
O(4)–V(1)–O(1) 93.7(2) 93.3(2) 92.44(7)
O(4)–V(1)–O(2) 94.0(3) 95.1(3) 96.31(7)
Fig. 3 The molecular structures of 1–3 with the atomic numbering scheme used.
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(Fig. 5C and D). These sets of complexes showed similar cytotoxi-
cities towards both cancer cells.
The complexes exhibited IC50 values in the ranges of 4.7–5.5
mM and 5.29–7.48 mM against HeLa and HT-29 cells (Table 5),
respectively. Out of the three complexes, the maximum cyto-
toxicity against HeLa cells was shown by 3, while the other two
complexes provided nearly the same IC50 values. A similar trend
was also seen for HT-29 cells, where 3 showed maximum
cytotoxicity, followed by 2 and 1. Also, it seems that there was
a tendency for higher toxicity of the compounds tested for HeLa
cells than that of the compounds tested for HT-29 cells. The
complexes showed higher antiproliferative activity as compared
to their corresponding ligands and metal precursors towards
both cancer cells (IC50 values4100 mM). In order to determine
the cytotoxic effect of the present complexes on the viability of
physiological cells, we performed a similar study on human
skin keratinocyte cells (HaCaT). It was noticed that there was
subtle decrease in the HaCaT cell viability upon increasing the time
of exposure of the complexes (5 mg mL1) from 12 to 24 h (Fig. 5E).
The results (Fig. 5F and Table 5) signify that unlike the observations
for the cancers cells, the complexes were less toxic towards HaCaT
at lower concentrations andwere cytotoxic only at concentrations of
50 mg mL1 and higher after 48 h of exposure. This can be an
indication that the complexes may be selective in nature towards
cancer cells. A feasible rationalization would be the decrease in
the polarity of the ligand and the central metal ion after charge
equilibration, which aids in the permeation of the complexes
through the lipid layer and the possible higher uptake by the cell
membrane.37 This consequently led to synergistic effects and
improved the cytotoxicity of the overall complex. Furthermore,
the presence of a naphthyl substituent13 in the ligand backbone
could be attributed to the lower IC50 value of 3 in comparison to
that of the other complexes.
Under similar experimental conditions, commonly used
chemotherapeutic drugs such as cisplatin and cyclophosphamide
have shown comparable eﬀectiveness against HeLa cells with
IC50 values of 12.2 and 1689 mM as well as against HT-29 cells
with IC50 values of 70 and 21.5 mM, respectively.
38 The present
series of vanadium complexes in the azohydrazone ligand
environment showed improved in vitro cytotoxicity results
against HT-29 cell lines in comparison to our previously
reported arylazovanadium(IV) complexes10e and other vana-
dium complexes (447 mM against HT-29 for [VO(sal-L-tryp)-
(acetylethTSC)]C2H5OH [VO(sal-L-tryp)(Me-ATSC)] and [VO(sal-L-
tryp)(N-ethhymethohcarbthio)]H2O),39 whereas the antiproliferative
potential of 1–3 was also better than or comparable to our
previously reported results for vanadium10 and molybdenum
hydrazone40 complexes against HeLa cells.
Fig. 4 Supramolecular architectures of (a) 1, (b) 2 and (c) 3. Dashed lines represent intramolecular (blue) and intermolecular (red) hydrogen bonds; for
clarity, only hydrogen atoms involved in these interactions are shown. For (c), only the more populated location of the disordered protonated amine is
shown.
Table 4 Hydrogen bond geometry for 1–3
Complex D–H  A D–H [Å] H  A [Å] D  A [Å] D–H  A [1]
1 N5–H5N–O4 0.86(3) 1.81(3) 2.668(9) 176(1)
2 N5–H5N–O4 0.90(3) 1.79(3) 2.681(9) 169(1)
O5–H5O-N1 0.95(8) 1.77(5) 2.589(9) 142(4)
3 O5–H5  N1 0.83(3) 1.84(3) 2.605(2) 151(2)
N5–H5B  O4a 0.86(2) 1.86(2) 2.711(2) 172(2)
a symmetry code: (i) x + 2, y + 1, z + 1.
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Nuclear staining assay. The mechanism of cell death in
response to the treatment with the complexes was studied through
the staining of dying cells with DAPI, which is a fluorescence dye
specific for nuclei.10e These DAPI-stained nuclei were used to check
the chromatin condensation or fragmentation during apoptosis
(type I programmed cell death), which is a hallmark feature of
nuclear alteration.10 Many cytotoxic agents and clinically active
compounds are known to disrupt the nuclear integrity and cytos-
keletal structure of the cells during their course of action,41 and
these include cisplatin (complexation of nucleic acids),42 doxo-
rubicin (intercalation of nucleic acids)43 and taxol (stabilization of
microtubules).44 Fig. 6 depicts the DAPI staining images of the
complexes against HeLa and HT-29 cell lines. It can be seen from
the images that the number of DAPI-stained nuclei decreased in
comparison to the control for both cell lines. Along with this, the
treated HT-29 cells exhibited shrinkingmorphology and condensed
chromatin bodies for all the complexes. In addition, the treated
HeLa cells also revealed nuclear blebbing and fragmentation.
Fig. 5 The eﬀect of 1–3 (3 mg mL1) on the cell viability of HeLa and HT-29 cells after 12 h (A) and 24 h (B) of exposure and after 48 h (C and D) of
exposure, taking 3, 5, 7, 10, 50, 100 mg mL1 concentrations of the complexes. The effect of 1–3 (5 mg mL1) on the cell viability of HaCaT after 12 h and
24 h (E) of exposure and after 48 h (F) of exposure, taking 5, 10, 50, 100 mg mL1 concentrations of the complexes. The cell viability was calculated by MTT
assay. Data were reported as the mean  SD for n = 4. *P o 0.05 was considered statistically significant.
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This phenomenon is a clear indication of apoptosis taking place
in the cells. Till date, there are a number of cytotoxic complexes
that have reported such a phenomenon and on this basis, we
hypothesize that this set of compounds may possess comparable
properties.10
Catalytic activity studies of 1–3
Oxidative bromination of thymol. There are various reports
in the literature on vanadium complexes behaving as structural
and/or functional mimics of vanadium haloperoxidases (VHPOs).45
These complexes can catalyze various oxidation reactions in the
presence of peroxides46 and organic substrates.47 Thus, in the first
case, the studied complexes (1–3) were used to evaluate their
efficiency towards the catalytic oxidative bromination of thymol
(a monoterpene) in the presence of KBr, 70% aqueous HClO4 and
30% H2O2 in an aqueous solution under appropriate reaction
conditions. All reactions were carried out in a 50 mL reaction flask
at room temperature. The bromination reaction occurred on the
most activated site as a result of electrophilic aromatic substitution
in the phenolic ring. Thus, the oxidative bromination of thymol led
to the formation of 2-bromothymol and 4-bromothymol, while
further bromination of these compounds also provided some
2,4-dibromothymol species (Scheme 2).
In order to obtain the best-suited reaction conditions
for maximum oxidative bromination products, the reaction
conditions were optimized considering 2 as a representative
catalyst. Thus, for 10 mmol of thymol (1.50 g), three diﬀerent
amounts of the catalyst (0.0005, 0.001, 0.002 g), three diﬀerent
amounts of 30% aqueous H2O2 (10, 20 and 30 mmol), three
diﬀerent amounts of KBr (10, 20 and 30 mmol) and three
diﬀerent amounts of 70% aqueous HClO4 (10, 20 and
30 mmol) were added in three equal portions to the reaction
mixture. The first portion was added at t = 0 and the other two
portions were added at 30 min intervals to 20 mL of water; the
reaction was carried out at room temperature for 2 h. The
amount of HClO4 added to the reaction mixture was found
to be crucial to obtain eﬀective catalytic bromination and
selectivity of products.
Table 5 IC50 values of 1–3 against HeLa, HT-29 and HaCaT cells after
48 h of exposure
Complex
IC50 (mM)
HaCaT cellsHeLa cells HT-29 cells
1 5.5  0.75 7.48  1.04 84.68  0.6
2 5.46  1.59 6.73  0.91 75.15  3.3
3 4.7  0.55 5.29  1.1 68.71  0.29
Fig. 6 Morphologies of HeLa (upper panel) and HT-29 (lower panel) cells treated with complexes 1–3 at a concentration of 10 mg mL1 for 24 h.
The cells were visualized under a confocal microscope after staining with DAPI (blue color, nucleus). The scale bar corresponds to 50 mm for the control,
while for the complexes, the scale bar corresponds to 25 mm.
Scheme 2 Products of the oxidative bromination of thymol.
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The details of all reaction conditions and the corresponding
conversions of thymol are summarized in Fig. 7 and Table 6.
The data presented in Table 6 are based on two sets of reactions
for each experiment, and the obtained conversions are within
1%. It may be concluded from the data presented in Table 6
that the optimized reaction conditions (entry no. 8) for the best
conversion of 10 mmol (1.50 g) thymol with catalyst 2 include
the use of 0.0005 g catalyst, 30 mmol 30% H2O2, 20 mmol KBr,
and 20 mmol 70%HClO4. Under these conditions, the obtained
conversion was 98%, where the selectivity of diﬀerent major
products followed the order 4-bromothymol (70%) 4 2,4-
dibromothymol (19%) 4 2-bromothymol (11%).
The other two catalysts, i.e., 1 and 3 were also tested under
the above-optimized reaction conditions, and the results are
presented in Table 7. It is clear from the data that both
complexes show similar catalytic activities (ca. 99%) (please
see Fig. 8 also) along with high turnover frequencies. Again,
4-bromothymol demonstrated the highest selectivity. A blank
Fig. 7 (a) The eﬀect of variation of the amount of catalyst 2 on the oxidative bromination of thymol. Reaction conditions: thymol (1.5 g, 10 mmol), 30%
aqueous H2O2 (1.13 g, 10 mmol), KBr (1.19 g, 10 mmol), and HClO4 (1.43 g, 10 mmol) at room temperature. (b) The eﬀect of variation of the amount of
oxidant on the oxidative bromination of thymol. Reaction conditions: thymol (1.5 g, 10 mmol), catalyst 2 (0.5 mg, 7.5  104 mmol), KBr (1.19 g, 10 mmol)
and HClO4 (1.43 g, 10 mmol) at room temperature. (c) The eﬀect of varying amounts of additive (KBr) on the oxidative bromination of thymol. Reaction
conditions: thymol (1.5 g, 10 mmol), catalyst 2 (0.5 mg, 7.5  104 mmol), 30% aqueous H2O2 (3.39 g, 30 mmol) and HClO4 (1.43 g, 10 mmol) at room
temperature. (d) The eﬀect of varying amounts of HClO4 on the oxidative bromination of thymol. Reaction conditions: thymol (1.5 g, 10 mmol), catalyst 2
(0.5 mg, 7.5  104 mmol), 30% aqueous H2O2 (3.39 g, 30 mmol) and KBr (2.38 g, 20 mmol) at room temperature.
Table 6 Conversion of thymol (1.5 g, 0.010 mol) using 2 as a catalyst, turnover frequency, and selectivity of diﬀerent products after 2 h of reaction under
diﬀerent reaction conditions
Entry KBr [g (mmol)] H2O2 [g (mmol)] HClO4 [g (mmol)] Catalyst [mg (mmol)] Conv. [%] TOF [h
1]
Selectivity [%]b
2-Brth 4-Brth 2,4-DiBrth
1 1.19 (10) 1.13 (10) 1.43 (10) 0.5 (7.5  104) 52 3466 13 82 5
2 1.19 (10) 1.13 (10) 1.43 (10) 1 (1.5  103) 44 1466 13 84 3
3 1.19 (10) 1.13 (10) 1.43 (10) 2 (3.0  103) 47 783 9 82 8
4 1.19 (10) 2.26 (20) 1.43 (10) 0.5 (7.5  104) 53 3533 10 67 23
5 1.19 (10) 3.39 (30) 1.43 (10) 0.5 (7.5  104) 61 4066 2 81 7
6 2.38 (20) 3.39 (30) 1.43 (10) 0.5 (7.5  104) 71 4733 11 73 16
7 3.57 (30) 3.39 (30) 1.43 (10) 0.5 (7.5  104) 68 4533 12 77 11
8a 2.38 (20) 3.39 (30) 2.86 (20) 0.5 (7.5  104) 98 6533 11 70 19
9 3.57 (20) 3.39 (30) 4.29 (30) 0.5 (7.5  104) 99 6600 12 46 42
a The optimized conditions mentioned here are the best among the diﬀerent sets of reactions carried out. b 2-Brth = 2-bromothymol, 4-Brth = 4-
bromothymol and 2,4-diBrth = 2,4-dibromothymol.
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reaction under the above reaction conditions led to only 38%
conversion (Table 7).
Comparing the present sets of complexes with those
reported in the literature, it was found that they showed similar
and even better conversion with higher turnover frequency
compared to previously reported [VVO(acac)(L)] [Hacac =
acetyl acetone, H2L = 6,60-(2-(pyridin-2-yl)ethylazanediyl)bis-
(methylene)bis(2,4-di-tert-butylphenol)] (ca. 99%),48 Cs(H2O)-
[VVO2{3,5-bis(2-hydroxyphenyl)-1-phenyl-1,2,4-triazole}] (99%),
49
and [K(H2O)2][VO2L] (H2L = ligands derived from 4,6-diacetyl
resorcinol and isonicotinoyl hydrazide, nicotinoyl hydrazide,
benzoyl hydrazide or 2-furoyl hydrazide) (90–98%),50 signifying
them as efficient catalysts for the oxidative bromination of
thymol. Interestingly, 3, which contained a naphthyl substituent
in the ligand backbone, showed the highest turnover frequency
among the series.
Oxidative bromination of styrene. In the second case, the
complexes (1–3) were also used to evaluate their efficiency
towards the catalytic oxidative bromination of styrene. We
again considered 2 as a representative catalyst, and the oxida-
tive bromination of styrene was carried out at room tempera-
ture in the presence of KBr, 70% aqueous HClO4 and 30%
aqueous H2O2 in water; this led to the formation of (a) 2-bromo-
1-phenylethanol and (b) 1-phenylethane-1,2-diol although
the literature reports the formation of one more product, i.e.,
1,2-dibromo-1-phenylethane (Scheme 3).22a,51,52
Consequently, the reaction was investigated by changing
diﬀerent parameters that may aﬀect the rate of styrene bromi-
nation and the selectivity of diﬀerent products. Thus, for
10 mmol of styrene (1.04 g, 10 mmol), three diﬀerent amounts
of catalyst (0.0005, 0.001, 0.002 g), three diﬀerent amounts of
30% aqueous H2O2 (10, 20 and 30 mmol), three diﬀerent
amounts of KBr (10, 20 and 30 mmol) and three diﬀerent
amounts of 70% aqueous HClO4 (10, 20 and 30 mmol) were
added in three equal portions to the reaction mixture as
mentioned above. The details of all reaction conditions and
the corresponding conversion of styrene are summarized in
Table 8 (please see Fig. S5, ESI,† also). From the data presented
in Table 8, it is clear that the optimized reaction conditions
(entry no. 8) for the maximum conversion of 10 mmol (1.04 g)
of styrene include the use of 0.001 g (1.5  103 M) of catalyst,
3.39 g (30 mmol) of 30% H2O2, 2.38 g (20 mmol) of KBr, and
2.86 g (20 mmol) of 70% HClO4. Under these conditions, the
obtained conversion was 99%, where the selectivity of the two
products followed the order 1-phenylethane-1,2-diol (71%) 4
2-bromo-1-phenylethanol (29%).
Table 7 Conversion, turnover frequency and selectivity parameters for
various catalysts for the oxidative bromination of thymol
Catalyst TOF [h1]a Conv. [%]
Selectivity [%]
2-Brth 4-Brth 2,4-DiBrth
1 5380 99 6 76 18
2 6533 98 11 70 19
3 7173 99 8 77 15
Without catalyst 38 3 84 13
a TOF values calculated at 2 h reaction time.
Fig. 8 Plots representing the conversion of thymol in the presence of 1–3.
Scheme 3 Expected products upon the oxidative bromination of styrene:
(a) 1,2-dibromo-1-phenylethane, (b) 2-bromo-1-phenylethane-1-ol and
(c) 1-phenylethane-1,2-diol.
Table 8 Conversion of styrene (1.04 g, 10 mmol) using 2 as a catalyst, turnover frequency, and product selectivity for 2 h of reaction under diﬀerent
reaction conditions
Entry KBr [g (mmol)] H2O2 [g (mmol)] HClO4 [g (mmol)] Catalyst [mg (mmol)] Conv. [%] TOF [h
1]
Selectivity [%]a
a b
1 1.19 (10) 1.13 (10) 1.43 (10) 0.5 (7.5  104) 43 2866 12 88
2 1.19 (10) 1.13 (10) 1.43 (10) 1 (1.5  103) 53 1766 14 86
3 1.19 (10) 1.13 (10) 1.43 (10) 2 (3.0  103) 47 783 13 87
4 1.19 (10) 2.26 (20) 1.43 (10) 1 (1.5  103) 65 2166 14 86
6 2.38 (20) 3.39 (30) 1.43 (10) 1 (1.5  103) 87 2900 19 81
7 3.57 (30) 3.39 (30) 1.43 (10) 1 (1.5  103) 88 2933 27 73
8* 2.38 (20) 3.39 (30) 2.86 (20) 1 (1.5  103) 99 3300 29 71
9 2.38 (20) 3.39 (30) 4.29 (30) 1 (1.5  103) 99 3300 20 80
10 2.38 (20) 3.39 (30) 4.29 (30) Blank 35 - 24 76
a a = 2-bromo-1-phenylethanol and b = 1-phenylethane-1,2-diol.
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As observed in earlier reports for cis-[VO2]-complexes,
51 the
reaction of the complexes with KBr in the presence of H2O2 and
HClO4 catalytically generated HOBr and/or Br
+, Br2, and Br
3,
which reacted with styrene to give bromonium ions as an
intermediate. The nucleophile Br as well as H2O may both
attack the a-carbon of the intermediate to give 1,2-dibromo-1-
phenylethane and 2-bromo-1-phenylethane-1-ol, respectively.
The nucleophile H2O may further attack the a-carbon of
2-bromo-1-phenylethane-1-ol to give 1-phenylethane-1,2-diol.52
All these justify the formation of 1-phenylethane-1,2-diol in the
highest yield.
The other two complexes, i.e., 1 and 3 were also tested under
the above-optimized reaction conditions for the maximum
conversion of styrene. The results are summarized in Table S1
and Fig. S6 (ESI†). It is clear from the data that the other two
complexes showed comparable catalytic activities (99%) along
with high turnover frequencies; between the two products, the
selectivity of 1-phenylethane-1,2-diol was always higher than
that of 2-bromo-1-phenylethanol. The blank reaction aﬀorded
only 35% conversion. Thus, these complexes have potential
catalytic activity.
The catalytic activity of the complexes towards the oxidative
bromination of styrene also compares well with the previous results
of [VVO(OEt)(EtOH)(L)] (H2L = Schiﬀ bases derived from 2-hydroxy-1-
acetonaphthone or 2-hydroxy-1-naphthaldehyde and salicylhydra-
zide, benzoylhydrazide and anthranylhydrazide) (96–97% conversion
with 63–69% selectivity towards diol)51 and [MoVIO2(X-Hsal-
dahp)(H2O)] [(X-sal = salicylaldehyde and its derivatives, dahp =
1,3-diamino-2-hydroxypropane) (97–99% conversion with 61%
selectivity towards diol)],52 showing increased conversion of 99%
with 75% selectivity towards the diol. Furthermore, the catalytic
activity of VO(acac)2 was also determined under the same reaction
conditions, where thymol gave 60  1% conversion, while styrene
gave ca. 65% conversion, which was less than that observed using
the complexes 1–3 reported here as catalysts.
Reactivity of complexes with H2O2. It has been previously
reported that dioxidovanadium(V) complexes upon reaction with
H2O2 provide the corresponding oxidoperoxidovanadium(V)
species.49 Similar species were generated for the present study
in MeCN and the progress of the reaction was monitored through
UV-vis spectroscopy. For all the complexes, similar observations
were made and as a representative, the results of 1 have been
discussed here. The gradual drop-wise addition of 30% H2O2
(0.108 g, 0.95 mmol) dissolved in 5 mL of MeCN to 25 mL of a
3.82  105 M solution of 1 in MeCN led to decrease in the
intensities of the 385, 341 and 291 nm bands (Fig. 9). This decrease
occurred due to the ligand-to-metal charge transfer and intra-
ligand transitions. These changes clearly suggested the formation
of oxidoperoxidovanadium(V) species in solution.48–50,53 The reac-
tivities of 2 and 3 are depicted in Fig. S7 and S8 (ESI†), respectively.
Conclusions
Concisely, this report presented the synthesis of three new
dioxidovanadium(V) complexes of tridentate binegative azo-
hydrazone ligands (H2L
1–3) and their characterization by
various analytical techniques (IR, UV-vis, 1H and 13C NMR
spectroscopy, ESI-MS and cyclic voltammetry). The molecular
structures of 1–3 were established by single-crystal X-ray
diffraction analysis, which revealed that vanadium was
present in distorted square pyramidal geometry with O4N
coordination spheres. These complexes were evaluated for
their in vitro cytotoxicity against HT-29 colon and HeLa
cervical carcinoma cells. Though all the complexes were found
to be cytotoxic in nature, 3 proved to be the most potent
among them. The cytotoxicity of these complexes may be due
to the azobenzene moiety in the ligand backbone synergizing
with different substituents along with the vanadium metal.
Furthermore, the catalytic potential of 1–3 was also tested
for the oxidative bromination of thymol and styrene. In
coherence with the antiproliferative activity, for all the cases,
the percentage of conversion (490%) was also found to be
significantly high in the presence of the catalysts with a high
turnover frequency. Especially, for the oxidative bromination
of thymol, the percentage of conversion and TOF were in the
ranges of 98–99% and 5380–7173 (h1), respectively. Besides,
for all the catalytic reactions, 3 showed the highest TOF value,
which may be due to the naphthyl substituent. Also, the
brominated organic compounds synthesized through the
oxidative bromination of the corresponding precursors
(thymol and styrene) using 1–3 as catalysts were identified
as useful starting materials for several organic transforma-
tions with biological and pharmaceutical importance.54 Again,
oxidative bromination reactions using these metal complexes
as catalysts can be considered as a favorable tool to replace
toxic and corrosive brominating agents (i.e., Br2).
54 Therefore,
the results of the present study stimulate further insights
into the mechanistic pathway of vanadium complexes in an
azohydrazone ligand environment in relation to their anti-
proliferative and catalytic activities and also to study the
correlation of the catalytic efficiency of these complexes with
their biological potential.
Fig. 9 Plots representing spectral changes during the titration of 1 with
H2O2. Spectra were obtained after the successive drop-wise addition of
30% H2O2 (0.108 g, 0.95 mmol) dissolved in 5 mL of MeCN to 25 mL of a
3.82  105 M solution of 1 in MeCN.
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